~~<i id='4AF77F7C2C'><strike id='4AF77F7C2C'><tt id='4AF77F7C2C'><pre id='4AF77F7C2C'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

author：hotspot 2025-10-04 09:08:25 Page View：7

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on
Next article： Moonlake's readout produced a cash windfall. Risks remain

Wikipedia

Trump demands the U.S. pay no more for drugs than other countries … again

EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

PhRMA sues HHS over Medicare drug price negotiation

PhRMAissuingtheBidenadministrationoveritsnewMedicaredrugpricenegotiationprogram.GraemeSloan/SipaUSAW

Affirmative action in medical school literally saved lives

AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

ICERPresidentStevenD.PearsonCraigF.Walker/TheBostonGlobeMeetingsoftheInstituteforClinicalandEconomic